Treatments with DPP4 inhibitors have been investigated for their ability to enhance engraftment following umbilical cord blood transplantation in adults with hematologic malignancies [46], to improve endothelial dysfunction, and to prevent major cardiovascular events in patients with type 2 diabetes [47–49]. This evidence concerns the gene DPP4 and hematologic disorder.